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Materials and Methods  
 
Mice 
 Male and female C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) 
were housed with unlimited access to standard laboratory chow and water until 
the start of each study. Mice were moved to individual filtered cages one day 
prior to study commencement and treatment administration. All treatment groups 
were subjected to a 12-hour day/night cycle and all experimental treatments were 
given at the same time of day for each treatment group. Maintenance of mice 
was performed by TES under the supervision of SAM and HAB. All murine 
experimental procedures have been approved and follow the regulations stated 
by the Animal Care and Use Committee (ACUC) at Ball State University. 
 Mice were between 8-10 weeks of age and ranged in body weight from 
15-29 grams. All treatments were administered per body weight and dosages 
given accordingly. Mice were divided into subgroups, no less than three mice per 
treatment group, to create experimental conditions with variation in sex, age, and 
weight. The treatment groups were simvastatin (#567020-50MG, Calbiochem) 
pre-treated + S. aureus-infected (Simva +) and saline/ethanol pre-treated + S. 
aureus-infected (Simva -). All experimental groups were administered gentamicin 
antibiotic at 3, 6, 12, and 24 hours post S. aureus infection.  
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 At the completion of each experimental set, mice were sacrificed using 
pentobarbital (10mg/ml) administered via intraperitoneal injection.  
Cell culture 
 Human umbilical vein endothelial cells (HUVEC) were maintained in 75cm2 
vented flasks containing filter sterilized M200 complete media (M-200-500, Cascade 
Biologicals) with Low Serum Growth Supplement (LSGS, S-003-10, Invitrogen) 
and incubated at 37oC with 5% CO2. Media was replaced three times weekly and 
cells were sub-cultured upon reaching 60% confluency. Sub-cultured conditions 
were aseptically completed using 0.25% Trypsin-EDTA (#25200, Invitrogen). 
HUVEC were used for flow cytometric analysis of tissue factor (TF). 
Staphylococcus aureus infection  
 S. aureus were sub-cultured from tryptic soy agar (TSA) slant stored at 
4oC into tryptic soy broth (TSB) 3 days prior to murine infection. TSB was 
inoculated using sterile loop and placed overnight on shaker (225rpm) at room 
temperature (RT). Sub-cultures were performed, as previously described, each 
day until infection. Sub-cultures of S. aureus were performed at the same time 
each day (3-4pm) to ensure sufficient bacterial growth and experimental 
consistency.  
 On the day of infection, overnight sub-culture of S. aureus were mixed and 
separated into 4 equal aliquots. Aliquots were spun at 10,0000 rpm, 370C for 3 
min., resuspended in pre-warmed sterile 0.85% saline, and re-spun as previously 
described. One aliquot was diluted in sterile saline and bacterial counts were 
made at 40X microscope objective using a hemacytometer. S. aureus was 
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diluted in 5% mucin to a bacterial count of 1 x 107 cells/ml for in vivo 
experimentation. All C57BL/6 mice were infected at time point 0 via 
intraperitoneal (i.p.) injection. S. aureus was diluted in sterile saline to a bacterial 
concentration of 3 x 108 cells/ml for in vitro experimentation.   
In vivo treatments 
 C57BL/6 mice were pre-treated at 20 hours and 3 hours prior to S. aureus 
infection via i.p. injection. Pre-treatments were administered at the same time 
point for each experimental group. Pre-treatment consisted of i.p. injection of 
simvastatin (1000ng/g body weight (BW)) rehydrated in 100% ethanol (EtOH) or 
saline/EtOH vehicle control. 
 Antibiotic treatment with gentamicin (10mg/kg BW) was administered at 3, 
6, 12, and 24 hours post S. aureus infection via i.p. injection. All treatment groups 
received antibiotic treatments. Murine specimens being sacrificed at 24 hours did 
not receive the 24 hour gentamicin injection.  
 Treatment groups included the experimental group, mice given 
simvastatin pre-treatment with gentamicin following S. aureus infection (Simva +) 
and the control group, mice given EtOH/saline pre-treatment with gentamicin 
following S. aureus infection (Simva -). Experimental collection was performed at 
24 and 48 hours post S. aureus infection for each treatment group and mice were 
sacrificed via lethal i.p. dose of pentobarbitol. 
 Whole blood and serum was collected via cardiac puncture and used for 
bacterial clearance study and TNF- enzyme linked immunosorbent assay 
(ELISA). 
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Clearance Study 
 Whole blood samples were collected via cardiac puncture at 24 and 48 
hours post S. aureus infection. All samples were plated immediately following 
collection to prevent clot formation. Whole blood samples were diluted in sterile 
saline at 1:10 for bacterial clearance study 1 to ensure the isolation of colony 
forming units (CFU). All future studies did not require the dilution of whole blood 
samples. For clearance study 1, whole blood and dilution samples were plated 
on pre-warmed TSA/7.5% sodium chloride (NaCl) plates for selective growth of 
S. aureus. All future bacterial clearance studies utilized only whole blood 
samples. Plates were incubated overnight prior to the start of the clearance study 
to ensure that plates were not contaminated. Experimental plates were incubated 
overnight at 37oC with 5% CO2. S. aureus bacterial colony counts were made 
following overnight incubation for each treatment and recorded for statistical 
analysis using SigmaStat and SigmaPlot.  
TNF- ELISA  
 TNF- Enzyme-linked immunosorbent assay (ELISA, #88-7324, 
eBioscience) were used to detect TNF- protein concentrations from C57BL/6 
serum. Whole blood was isolated via cardiac puncture at 24 hour and 48 hours 
post S. aureus-infection, as previously described. Serum was separated at 4oC 
via centrifugation. Samples were run in a 96-well plate using manufacturer 
protein standards. Plate was coated with 1:250 dilution of capture antibody 24 
hours prior to sample running, wells were washed with 1X PBS/ 0.05% Tween-20 
(#P5927-100ML, Sigma) wash buffer, and incubated in 5X assay diluent. All well 
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rinses used same wash buffer. Two-fold serial dilutions of standard were 
performed to included concentration values of 0.5pg/ml - 1000pg/ml. Serum 
sample dilution were performed 1:5 to included values between 1:5-1:625. A 
dilution of Biotin-conjugate anti-mouse TNFa polyclonal detection antibody 
(1:250) and Avidin-HRP enzyme (1:250) were added to all samples. 10 M sulfuric 
acid (H2SO4) (2N) (#339741-100ML, Sigma) stop solution was used to halt 
reaction and plate was immediately read at 450nm using a Bio-Rad microplate 
reader. Treatment groups will be compared and data will be analyzed using One-
way ANOVA with post-hoc analysis.  
Flow cytometric analysis of TF in HUVEC 
 HUVEC were cultured in M200 as previously described and plated in 35-
mm plates (Fisher Scientific #08-772 A) pre-coated with attachment factor (AF, 
S-006-100, Invitrogen) at 5 x 104 cells/plate and incubated at 37oC with 5% CO2. 
Treatments groups consisted of cells pre-treated with simvastatin or dimethyl 
sulfoxide (DMSO, control, #D128-500, Fisher). Experimental groups were S. 
aureus-uninfected/ 0.01% DMSO, S. aureus-infected/ 0.01% DMSO, S. aureus-
uninfected/ 1M simvastatin, and S. aureus-infected/ 1M simvastatin. HUVEC 
were pre-treated 24 hours post-initial plating procedure and incubated at 37oC 
with 5% CO2.  
 HUVEC were infected with 3 x 108-cfu S. aureus on day three following 
initial plating. Plates containing pre-treatment were washed in 1X sterile 
phosphate buffered saline (PBS, #20012-043, Invitrogen), replaced with 10% 
FBS/PBS for opsonization, and infected with S. aureus or saline control for 1 
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hour and 6 hours at 37oC with 5% CO2. Following 1 hour infection, designated 
HUVEC were washed in 1X PBS and given 50 g/ml of gentamicin (Sigma G 
1272)/20 g/ml lysostaphin (Sigma L-7386) in 10% FBS/PBS and returned to 
incubation. 
 All HUVEC treatments were harvested on ice at 6 hours post-infection. 
Cells were scraped, placed into pre-chilled FACS tubes, and spun at 
1500rpm/4oC for 5 minutes. Anti-TF antibody CD142 (#550312, BD) was added 
to samples (excluding controls), samples were incubated on ice for 30 minutes. 
Following incubation, FACS buffer was added to cells, samples were spun as 
previously described, set with FACS and Fix, and analyzed via flow cytometric 
analysis. 
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Results 
 
 Previous studies indicated the ability of simvastatin to increase survival rates in 
S. aureus infected C57BL/6 mice. In order to establish a possible mechanism to explain 
this increased survivability, we wanted to look at possible innate immune responses to 
S. aureus in the presence of simvastatin. Bacterial clearance studies were performed as 
the first means to determine whether simvastatin increases survivability by enabling 
mice to clear S. aureus bacterial infection more efficiently than EtOH pre-treated control 
mice. 
 C57BL/6 mice, randomly assigned to treatment groups, consisted of male and 
female mice, 8-10 weeks of age. Whole blood isolated via cardiac puncture was plated 
on TSA / 7.5% NaCl agar plate for selective growth of S. aureus at 24 and 48 hours 
post infection. Colony forming units (cfu) were counted following 24 hour incubation at 
37oC with 5% CO2. Statistical analysis using SigmaStat/SigmaPlot found there to be no 
statistical significance in the number of S. aureus cfu in mice pre-treated with 
simvastatin or EtOH control (Figure 1). Results indicate that bacterial clearance is not 
enhanced in the presence of simvastatin at 24 or 48 hours post S. aureus infection in 
C57BL/6 mice. At 48 hours post infection, all S. aureus cleared regardless of the 
indicated treatment (Figure 1B).  
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Figure 1. Simvastatin pre-treatment did not enhance S. aureus bacterial clearance in 
C57BL/6 mice. Mice (n=8-16 per group) were pre-treated with 1000ng/g simvastatin 
(+Simva) or given ethanol control (-Simva). Both treatment groups were given 
gentamicin (10mg/kg) post S. aureus infection. Whole blood was isolated from control 
and simvastatin-treated mice 24 hours (A) and 48 hours (B) post infection and plated on 
TSA plates. Colony forming units were counted on each plate after 24 hours. No 
statistical difference was determined in the number of colony forming units between 
treatment groups as determined by student’s t-test. 
 
 Since clearance of S. aureus was not enhanced due to simvastatin pre-
treatment, we evaluated innate immune responses to bacterial infection. TNF-α, a major 
pro-inflammatory cytokine involved in inflammation, was analyzed using ELISA 
techniques.  Mice were experimentally divided as previously described. Serum was 
separated from whole blood extracted via cardiac puncture and used for TNF-α ELISA. 
At 24 hours (Figure 2A) and 48 hours (Figure 2B) post S. aureus infection, there is no 
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statistical difference in TNF-α concentration in mice pre-treated with simvastatin 
compared to mice pre-treated with EtOH control as evaluated by student’s t-test. There 
is; however, an apparent immunological trend in the idea that simvastatin may play a 
role in decreasing TNF-α secretion, thereby reducing the inflammatory effects of 
infection. Simvastatin may promote the down regulation of innate immune responses, 
leading to decreased in pro-inflammatory cytokine secretion which decreases 
inflammation caused by S. aureus infection. 
 
 
 
 
 
Figure 2. Simvastatin pre-treatment does not significantly reduce TNF- levels in S. 
aureus-infected C57BL/6 mice. Mice were pre-treated with 1000ng/g simvastatin 
(+Simva) or given ethanol control (- Simva). Both treatment groups were given 
gentamicin (10mg/kg) post S. aureus infection. Serum was isolated all treatment mice at 
24 hours (A) and 48 hours (B) post infection and used for TNF-α ELISA. No statistical 
difference was found in TNF-α concentration between treatment groups. 
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 In vivo experimentation can be difficult due to variability. The last experiment in 
our current study involved in vitro analysis of TF in HUVEC. HUVEC pre-treated with 
simvastatin or DMSO control were evaluated for the presence of TF expression post S. 
aureus infection via flow cytometry. HUVEC were tagged with anti-TF antibody to 
determine if TF was present in more abundance on cells pre-treated with simvastatin as 
compared to the DMSO control. Flow cytometric analysis found that there is no 
decrease in TF expression in S. aureus-infected HUVEC pre-treated with simvastatin as 
compared to control (Figure 3, Figure 4). Flow cytometry determined there to be a 
significant increase (*) in TF expression in S. aureus-infected DMSO control cells as 
compared to uninfected cells (Figure 3). The trend indicates that S. aureus infection 
increases the expression of tissue factor. There was no difference found in TF 
expression between uninfected DMSO or uninfected simvastatin pre-treated HUVEC 
(Figure 3). The main result determined, indicates that simvastatin does not decrease the 
expression of TF in S. aureus infected HUVEC (Figure 4). Since TF induces the 
coagulation cascade, a reduction of TF expression in response to simvastatin might 
decrease the deleterious effects of over-induction of coagulation is response to S. 
aureus infection.  
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Figure 3. Simvastatin pre-treatment does not decrease tissue factor expression in S. 
aureus-infected human HUVEC. *S. aureus infection increases the expression of tissue 
factor in DMSO cells. Human umbilical vein endothelial cells (HUVEC) were pre-treated 
with 1μM simvastatin (Simva) or 0.01% dimethyl sulfoxide (DMSO) for 24 hours prior to 
S. aureus infection. The percentage of tissue factor positive cells in the total cell 
population was measured via flow cytometry. No statistical difference was observed 
between infected cells pre-treated with simvastatin or DMSO as determined by one-way 
ANOVA with post hoc analysis. * p<0.05 
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Figure 4. Simvastatin pre-treatment does not significantly decrease tissue factor 
expression in S. aureus-infected human HUVEC cells. Human umbilical vein endothelial 
cells (HUVEC) were pre-treated with 1μM simvastatin (Simva) or 0.01% dimethyl 
sulfoxide (DMSO) for 24 hours prior to S. aureus infection. The percentage of tissue 
factor positive cells in the total cell population was measured via flow cytometry. No 
statistical difference was observed between infected cells pre-treated with simvastatin 
or DMSO as determined by one-way ANOVA with post hoc analysis. Adapted from 
figure 3. 
 
 
 The results of our current study were not significant; however, simvastatin may 
be working to reduce the secretion of some major pro-inflammatory cytokines and 
mediators involved in the innate immune response to S. aureus. The cytokines and 
protein mediators affected by simvastatin may include TNF- and TF. These mediators 
may have an effect on the resulting inflammatory responses produced from infection 
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with S. aureus. A closer look into the immunomodulatory role that statins play in innate 
immune responses to S. aureus may lead to a more conclusive understanding of the 
protective effects that simvastatin may have against sepsis. 
 
